论文部分内容阅读
恶性肿瘤致死的主要原因是肿瘤转移.在过去几年里,新的诊断技术和肿瘤免疫治疗研究已经取得突破性进展.对乳腺癌、肺癌和结肠癌等癌症的临床研究表明:检测出癌症病人骨髓中微小转移灶对判定病人的预后有重要价值,并为肿瘤转移的诊断提供了有力证据.另外,两种以单克隆抗体（mAb）为基础的免疫治疗已被批准用于上皮细胞癌临床治疗.MAb17-1A在人结肠、直肠癌以及mAbherceptin在乳腺癌治疗中均已取得良好的疗效.利用其他抗肿瘤抗体的免疫治疗也已经取得明显的临床治疗效果.这些研究结果提供了一种对付上皮细胞癌微小转移灶的新治疗策略,即检测循环系统中的微小转移灶以及通过免疫治疗清除这些转移癌细胞.
The leading cause of death from malignancies is tumor metastasis, and breakthroughs have been made in new diagnostic techniques and cancer immunotherapy research over the past few years. Clinical studies of cancers such as breast, lung and colon cancer show that cancer patients Micrometastases in the bone marrow are of great value in determining the prognosis of patients and provide strong evidence for the diagnosis of tumor metastases. In addition, two monoclonal antibody (mAb) -based immunotherapies have been approved for clinical use in epithelial cell carcinoma Treatment.MAb17-1A in human colon, rectal cancer and mAbherceptin have achieved good results in the treatment of breast cancer.The use of other anti-tumor antibody immunotherapy has also made significant clinical treatment of these findings provide a counter New therapeutic strategies for micrometastases of epithelial cancers, ie detecting micrometastases in the circulatory system and clearance of these metastatic cancers by immunotherapy.